Prudential Financial Inc. has reimbursed 437 individuals a total of approximately 2.85 billion yen ($17.4 million) in remediation payments tied to a review of employee misconduct at its Japan business, a review that followed an order from Japan's Financial Services Agency for the insurer to undertake a fundamental review of its organizational structure.
The reimbursements stem from an internal investigation earlier this year that found more than 100 former employees in Japan had engaged in improper investment solicitation, misconduct that resulted in more than $20 million in damages to the insurer's local clients. Prudential has suspended new life insurance sales in Japan for the duration of the regulatory review, with the suspension currently running until Nov. 5.
According to a company filing made on Friday, the reimbursement program has expanded in scope since it was first disclosed. In addition to the 498 individuals who presented claims as announced on Jan. 16, an independent panel established by the company has since reviewed 365 further individual inquiries. Of those, 125 claims, representing 792 million yen, were found eligible for reimbursement. In the same filing, the company said it is running programs to inform customers and continuing its own inquiries into the conduct, while overhauling how the Japan business is managed to guard against a repeat. It also confirmed it will provide quarterly updates on the reimbursement program as the review continues.
The remediation costs and the sales suspension have already registered in Prudential's international results. In May, the company reported that adjusted operating income for its international businesses fell 4% in the first quarter of 2026 compared with the same period a year earlier, a decline it attributed primarily to higher expenses connected to the Japan suspension. That earnings drag sits alongside the newly disclosed reimbursement figures, meaning the cost of the episode is showing up both in direct claims payments and in the broader income statement for as long as new sales remain suspended.
Market reaction has been more muted than the operational disruption might suggest: shares of the company have rebounded since mid-March, recouping almost all of the losses recorded after the misconduct findings first became public. With the suspension running until Nov. 5 and further quarterly reimbursement disclosures still to come, the eventual size of the remediation bill, and its continued effect on international operating income, will depend on how many further claims are found eligible before the Japan business resumes new sales.
